This commentary discusses the findings of a randomized clinical trial of trastuzumab vs a biosimilar in patients with metastatic breast cancer that was published in JAMA and posits 3 questions for consideration moving forward in the development and clinical use of biosimilars.
http://ift.tt/2kqSrkQ
Εγγραφή σε:
Σχόλια ανάρτησης (Atom)
-
Abstract The changes of dissolved organic matter (DOM) components during stabilization process play significant effects on its redox prope...
-
Publication date: September 2017 Source: European Journal of Surgical Oncology (EJSO), Volume 43, Issue 9 http://ift.tt/2gezJ2D
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου